Prestige Consumer Healthcare (PBH) 28th Annual Needham Growth Conference Virtual summary

Business resilience and portfolio strategy

• Maintained strong performance in 2025 despite external disruptions like tariffs, government shutdowns, and regulatory changes.

• Focused on essential healthcare products that remain in demand regardless of economic conditions.

• Emphasized brand building through innovation, targeting unmet consumer needs and expanding categories rather than just gaining market share.

• Dramamine's growth driven by product extensions such as non-drowsy and Ginger Chews, attracting new users and expanding use cases.

• Portfolio diversification allows for stability, as strong performance in some categories offsets weaker ones during market shifts.

Distribution and channel evolution

• Broad distribution strategy ensures presence wherever consumers shop, including mass retail and e-commerce.

• Significant investment in e-commerce has led to double-digit growth on Amazon, while traditional drug and grocery channels see declines.

• Consistent pricing and profitability across channels, with no negative impact from consumer channel shifts.

Brand recovery and supply chain

• Clear Eyes recovery involves securing supply through new suppliers and the Pillar5 acquisition, with sequential shipment improvements expected through fiscal 2027.

• Focus on rebuilding retailer inventory and reconnecting with consumers as more SKUs return to shelves.